<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "cystic fibrosis" and "editing" OR "therapy" OR "therapies"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: High-risk multimorbidity patterns on the road to cardiovascular mortality.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32151252">Link</a></p><p><b>Date:</b> 03/10/2020</p><p><b>Authors:</b> Nils Haug ...  Peter Klimek</p><p><b>Journal:</b> BMC Med</p><p><b>IF (7 or above):</b> 8.41</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Multimorbidity, the co-occurrence of two or more diseases in one patient, is a frequent phenomenon.  Understanding how different diseases condition each other over the lifetime of a patient could significantly contribute to personalised prevention efforts.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31841044">Link</a></p><p><b>Date:</b> 12/16/2019</p><p><b>Authors:</b> Dinesh Khanna ...  John Varga</p><p><b>Journal:</b> Am. J. Respir. Crit. Care Med.</p><p><b>IF (7 or above):</b> 12.18</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease.  Lung fibrosis occurs in âˆ¼80% of patients with SSc; 25% to 30% develop progressive interstitial lung disease (ILD).</p></div></td></div></tr></table></div><hr></div></body></html>